

## NEWS RELEASE

Media contact: Dan Shuman  
daniel\_shuman@lifenethealth.org  
757-609-4330, office  
757-374-5316, cell

### **LifeNet Health features innovative LifeSciences programs at BIO International Convention**

*LifeNet Health selected to present on predictive oncology drug-screening platform  
during June 5 innovative technology session*

**Boston, Mass.** — June 4, 2018 — [LifeNet Health](#) will feature its growing portfolio of unique, high-quality biospecimens for research at the [BIO International Convention](#) June 4-7 in Boston (Booth #2414). Through its [LifeSciences Division](#), the regenerative medicine company is focused on providing transplant-quality organs and tissues, innovative drug discovery platforms and isolated primary cells.

LifeNet Health also will present its predictive and translational oncology drug-screening platform, HuBiogel™, during a [BIO-sponsored innovative technology session](#) at 4:15 p.m. Tuesday, June 5, in the exhibition hall. The presentation, by Chief Scientist Raj Singh, PhD, also [will be broadcast on live webcast](#).

“HuBiogel’s novel technology provides fully-human tumor assay products and services that allow accurate preclinical and translational research,” said Jingsong Chen, MD, Chief Technology Officer at LifeNet Health. “Unlike 2D cell-based models, microtumor models can replicate multicellular growth, angiogenesis, hypoxia and invasion processes *ex vivo*.”

BIO attendees can visit the LifeNet Health exhibit or meet in person at the partnering session with the LifeSciences team to learn more about high-quality primary cells, HuBiogel oncology services, HuGentra® human extracellular matrix, and the organization’s organ and tissue recovery programs for research. Some of the featured human cell types include hepatocytes, pancreatic islets, dermal fibroblasts, epidermal keratinocytes, and renal epithelial cells in addition to many others.

“LifeNet Health is uniquely prepared to be a catalyst for pioneering advances in drug discovery by meeting the need for organs, tissues and cells in research,” said Rony Thomas, LifeNet Health President and CEO. “Our technologies ensure that the resources we provide can support breakthrough translational research, helping accelerate new therapies from the lab to the patient.”

The LifeSciences Division is focused on innovative, technology-driven preclinical research programs. The result of this effort is a human tissue- and cell-based *in vitro* biology platform, supported by vertically integrated recovery and preparation processes. This program serves the growing need for human biospecimens, 3D tissue models, primary cells and hepatocytes for scientific research, drug discovery and safety testing.

#### **About LifeNet Health**

LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world’s most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to [www.lifenethealth.org](http://www.lifenethealth.org).

###